Longeveron LLC (LGVN)
Longeveron LLC is a healthcare company focused on biotechnology and cellular medicine. The company is developing treatments for age-related and serious medical conditions in the United States. Its lead candidate, LOMECEL-B, is an allogeneic mesenchymal stem cell product derived from the bone marrow of young, healthy adult donors. LOMECEL-B is being studied in a phase 3 trial for hypoplastic left heart syndrome, and it has also been tested in a completed phase 2a study in Alzheimer’s disease and a phase 2b trial in frailty associated with aging. Founded in 2014, Longeveron is headquartered in Miami, Florida. The listed security is common stock on NASDAQ under the ticker LGVN.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-LGVN
|
$4.12
|
51.4% Upside
|
Bargain
|
$61.25 2,151.8% Upside
|
Not available
|
Bargain
|
Weak
|
0.0%
|
November 6, 2026
|
0.8x
|
6.6x
|
8.672 M
|
-1.685 M
|
6.3%
|
74.6%
|
-38.1
|
87.5%
|